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Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis. VEGF expression in metastatic renal cell
carcinoma (mRCC) is mostly regulated by hypoxia, predominantly via the hypoxia-induced factor (HIF)/Von Hippel-Lindau
(VHL) pathway. Advances in our knowledge of VEGF role in tumor angiogenesis, growth, and progression have permitted
development of new approaches for the treatment ofmRCC, including several agents targeting VEGF andVEGF receptors: tyrosine
kinase pathway, serine/threonine kinases, 𝛼5𝛽1-integrin, deacetylase, CD70, mammalian target of rapamycin (mTOR), AKT, and
phosphatidylinositol 3󸀠-kinase (PI3K). Starting from sorafenib and sunitinib, several targeted therapies have been approved for
mRCC treatment, with a long list of agents in course of evaluation, such as tivozanib, cediranib, and VEGF-Trap. Here we illustrate
the main steps of tumor angiogenesis process, defining the pertinent therapeutic targets and the efficacy and toxicity profiles of
these new promising agents.
1. Introduction
The development of targeted agents has completely changed
the therapeutic landscape of metastatic renal cell carcinoma
(mRCC). Starting from sorafenib in 2005, several agents
have been sequentially approved by the US Food and Drug
Administration (FDA), such as sunitinib, bevacizumab plus
interferon, everolimus, temsirolimus, pazopanib, and at last
axitinib. Nevertheless, despite recent success, complete
responses to antiangiogenic therapies are rare, and patients
do progress in response to antivascular endothelial growth
factor (VEGF) targeted therapies. The increasing awareness
of themolecularmechanisms underlying tumor angiogenesis
in RCC parallels the development of novel antiangiogenic
agents, mainly directed against VEGF-A, platelet-derived
growth factor (PDGF) receptors (PDGFRs), and VEGF
receptor-2 (VEGFR-2), with a list of novel targets currently
in course of evaluation.
In RCC, the loss of 3p induces a high incidence of Von
Hippel-Lindau (VHL) tumor suppressor gene inactivation,
which promotes hypoxia-inducible factor-1 (HIF-1) dysreg-
ulation [1], and leads to increased expression of VEGF and
other proangiogenic factors [2]. HIF-1 activity is essential
for genetic stability, proliferation, migration, and survival,
contributing also to tumor cell metabolism and drug and
radiation resistance [3, 4].
Tumor angiogenesis is the result of the interaction among
several components of tumor microenvironment. This mul-
tistep process involves the migration and proliferation of
endothelial cells (ECs), the recruitment of hematopoietic pro-
genitor cells (HPCs), highly proliferative circulating endothe-
lial cells (CECs), and endothelial progenitor cells (EPCs), the
detachment and migration of pericytes, and the cooption
of neighbouring preexisting vessels [5]. Several signaling
pathways are involved in tumor angiogenesis, such as VEGF,
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Figure 1: RCC tumor angiogenesis. (a) Factors influencing promotion of tumor angiogenesis. (b) Tumor vessel sprouting andmetastasis. Ang-
1; angiopoietin-1; FGF; fibroblast growth factor; PDGF; platelet derived growth factor; RCC; renal cell carcinoma; VEGF; vascular endothelial
growth factor.
which plays a crucial role inRCCcarcinogenesis [6, 7], PDGF,
the mammalian target of rapamycin (mTOR), VHL, a tumor
suppressor gene, andHIF (Figure 1).The transit from an anti-
to a proangiogenic phase, also called angiogenic switch, leads
to the rapid formation of blood vessels [8]. The insufficient
vascularisation accompanying rapid tumor growth leads to
hypoxia [9, 10].
VEGF promotes EC migration and proliferation, thus
stimulating extracellular matrix (ECM) and EC basement
membrane digestion by plasminogen activator (PA) andmet-
alloproteinases (MMPs). Tumor vessel sprouting requires, at
first, the removal of pericytes from preexisting blood vessels.
As a result of this process, ECs begin to proliferate and
migrate to form new vessels, subsequently surrounded by
mesenchymal cells differentiated into pericytes. Tumor cell-
derived VEGF induces also the recruitment of CECs and
EPCs. CECs are generally accepted as cells expressing the von
Willebrand factor (vWf), CD146, CD34, and VE-cadherin.
Their clinical significance is still under investigation. Recent
studies have observed increased levels of CECs in RCC
patients treated with sunitinib, likely caused by the drug tar-
geting of immature tumor vessels [11]. EPCs express CD133,
CD34, and VEGFR-2 [12]. Circulating EPCs begin to differ-
entiate by loosing the CD133 marker and gaining EC-specific
markers such as vWf, CD31, and VE-cadherin [13], thus
enhancing tumor development and growth [14]. In 2003, Rafii
et al. observed that MMP-9 was capable of mobilizing EPCs
[15]. Their migration is mediated by the chemokine stromal-
cell-derived factor-1(SDF-1), which is upregulated during
hypoxia [16].
A related circulating cell population is the HPC, express-
ing VEGFR1. Along with EPCs expressing VGFR2, they col-
onize the sprouting vessel connective tissue and also provide
growth factors and cytokines to create a microenvironment
favouring the start of metastatic process, in which tumor cells
can localize and proliferate [17]. Recently, Powles et al. have
demonstrated the association between increased numbers of
circulating HPCs and poor outcome in patients with mRCC
treated with sunitinib [18].
The complete formation of a lumen in novel sprouting
vessels needs the contribution of stalk cells, stimulated by
VEGF, ECM, and EC-derived EGF-like domain 7 (Egfl7),
which promotes the separation and proper spatial arrange-
ment of the angioblasts and allows subsequent assembly of
vascular tubes [19].
Thedetachment of pericytes during tumor angiogenesis is
mediated by VEGF and angiopoietin-2 (Ang-2)/type I tyro-
sine kinase receptor 2 (TIE 2). The moved pericytes are
recruited by PDGF expressed in ECs, surrounding and stabil-
izing vessel sprouts [20].
The expression of angiogenic factors in RCC is also
regulated by VHL-independent signaling pathways, such as
the oncoprotein homologue of the mouse double minute 2
(HDM2) that leads to the constitutive expression of HIF𝛼.
HDM2 also regulates the protein levels of HIF angiogenic
targets, such asVEGF, PA inhibitor-1 (PAI-1), and endothelin-
1 (ET-1) [21].
Therefore, in this review we illustrate the progress of
molecular targeted therapy, describing the emerging agents in
course of evaluation and the future directions in the treat-
ment of RCC patients.
2. Tyrosine Kinase Inhibitors
‘‘Enlarged’’ Family
In the last two years, the list of novel anti-angiogenetic agents
under evaluation has progressively enlarged, including now
axitinib, tivozanib, dovitinib, cediranib, linifanib, volocix-
imab, regorafenib, and other new emerging molecules [22].
In January 2012, axitinib was approved in the second line
treatment of mRCC patients. Axitinib is an oral inhibitor
of VEGFR, PDGFR, and c-kit, and it may afford a relevant
contribution for the futuremanagement of RCC patients. In a
phase II trial enrolling 62 treatment-refractory RCC patients
progressed on sorafenib and treated with oral 5mg axitinib
twice daily, the median progression-free survival (PFS) was
7.4 months. Grades 3 to 4 adverse events included hand-
foot syndrome (16.1%), fatigue (16.1%), hypertension (16.1%),
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dyspnea (14.5%), diarrhea (14.5%), dehydration (8.1%), and
hypotension (6.5%) [23]. In addition, another phase II trial
with axitinib, enrolling cytokine-refractory nephrectomised
patients, showed response rate (RR) of 44.2% and a median
time to progression (TTP) of 15.7 months [24]. The AXIS
phase III trial, comparing the effectiveness of axitinib and
sorafenib in pretreated advanced RCC patients, has shown a
significant median PFS (6.7 versus 4.7 months), with a more
pronounced benefit for patients after immunotherapy (12.1
versus 6.5 months) [25]. With regard to the front-line use of
axitinib, the preliminary results shown at the 2012 annual
meeting of the American Society of Clinical Oncology
(ASCO) from the randomized phase II study AGILE 1046
demonstrated a median PFS of more than 1 year and an
overall response rate of 40.2% for axitinib [26]. Furthermore,
several trials are presently ongoing to evaluate the role of axi-
tinib as neoadjuvant therapy (NCT01263769), in combination
with everolimus (NCT01334073), or coadministered with
PF-04856884, a selective angiopoietin (Ang)-2 inhibitor
(NCT01441414).
Among the emerging agents, tivozanib (AV-951) has
been demonstrated to be effective in the first line setting of
mRCC patients with prior nephrectomy [27]. Tivozanib is
a potent inhibitor of VEGFR-1, 2, and 3, cKit, and PDGFR.
Hypertension (50.0%) and dysphonia (21.7%) were the most
commonly reported treatment-related adverse events of any
grade. There was a low incidence of diarrhea (12.1%), fatigue
(8.1%), stomatitis (4.4%), and hand-foot syndrome (3.7%).
In the phase III “TIVO-1” study [28], a total of 517 patients
were randomized to tivozanib (𝑁 = 260) or sorafenib (𝑁 =
257) in first line advanced RCC patients. Tivozanib showed
a statistically significant improvement in median PFS com-
pared to sorafenib (11.9 versus 9.1 months) in the subpopula-
tion of patients who were pretreated with systemic therapy
including cytokines. In patients who were treatment naı̈ve
(70% of total study population), tivozanib showed a statis-
tically significant improvement in PFS, with a median PFS
of 12.7 months compared with 9.1 months for sorafenib (HR
0.756, 95% CI 0.580–0.985; 𝑃 = 0.037). Tivozanib demon-
strated favorable tolerability, with a lower rate of dose inter-
ruptions (18% versus 35%, 𝑃 < 0.001) and reductions (14%
versus 44%, 𝑃 < 0.001). The most common ≥grade 3 adverse
events (AEs) due to tivozanib compared to sorafenib were
hypertension (25% versus 17%), hand-foot syndrome (2%
versus 17%), diarrhea (2% versus 6%), fatigue (5% versus 4%),
and neutropenia (2% versus 2%). While the progression-free
survival was improved, the overall survival (OS) showed a
trend toward a detrimental effect with the tivozanib arm
with a median OS of 28.8 months versus 29.3 months in the
sorafenib arm based on the pre-new drug application (NDA)
meeting with the US Food and Drug Administration (FDA)
[29] which later led to the FDAODACmeeting to disapprove
tivozanib as an indication for RCC.
A phase I study has been completed to evaluate the safety
of tivozanib in combination with temsirolimus in subjects
with mRCC (NCT00563147).
With regard to the third line treatment ofmRCC patients,
dovitinib seems to represent a valid option. It is a fibrob-
last growth factor receptor (FGFR) and VEGFR inhibitor,
presently in course of evaluation in a phase III trial
(NCT01223027). The most common adverse events shown
in the phase I/II study were nausea (80%; G3:5%), diarrhea
(70%), vomiting (65%), asthenia (50%; G3:15%), anorexia
(45%; G3:5%), headache (30%; G3:5%), hypertension (25%;
G4:5%), and rash (23%;G3:5%). In a phase II trial enrolling 59
previously treated patients, dovitinib was administered with
a dose schedule of 500mg/day 5 days on/2 days off. In this
study, PFS and OS were 6.1 and 16 months, respectively [30].
Results are awaited from a phase III trial (NCT01223027)
enrolling 550 patients who must have received one VEGF-
targeted therapy and one prior mTOR inhibitor therapy to
evaluate dovitinib versus sorafenib in the third line setting of
mRCC treatment.
Recent advances in understanding the role of fibroblast
growth factor 2 (FGF2) and FGF receptor (FGFR) in mod-
ulating resistance to sunitinib [31] led to the development
of PD173074, a reversible FGFR and VEGFR inhibitor. Thus,
FGF2 supports endothelial proliferation and de novo tubule
formation in the presence of sunitinib, suppressing sunitinib-
induced retraction of tubules. Currently, several studies are
analyzing the efficacy and safety of PD173074 in small cell
lung cancer and RCC.
At this time, the list of emerging TKIs under study in
phase II trials includes cediranib, linifanib, regorafenib, briv-
anib, vandetanib, lenvatinib, and several other agents. Cedi-
ranib (AZD2171) is an oral inhibitor of VEGFR1-3, PDGFR𝛽,
and c-kit. In 2012, Mulders et al. have published the results
from a phase II trial (NCT00423332) in 71 previously
untreated mRCC patients randomized to receive cediranib
(𝑛 = 53) or placebo (𝑛 = 18). They revealed 34% PR and 47%
stable disease (SD), and cediranibwas generally well tolerated
[32]. Furthermore, another phase II trial (COSAK) is ongoing
to assess the efficacy of cediranib 30mg versus cediranib
30mg plus 175mg saracatinib (AZD0530), an Src Family oral
inhibitor, in patients with relapsed metastatic clear cell RCC
(ccRCC).
Linifanib (ABT-869) is a potent inhibitor of VEGFR,
PDGFR, fms-like tyrosine kinase 3 (FLT3), c-kit, and colony
stimulating factor-1 receptor (CSF1R). In 2012, Tannir et al.
have published their results [33] from an open-label multi-
center trial (NCT00486538) in 53 patients previously treated
with sunitinib, receiving oral linifanib 0.25mg/kg (12.5–
25.0mg) daily. They showed 13.2% overall RR, with a median
PFS and OS of 5.4 and 14.5 months, respectively.
Regorafenib (BAY 73-4506) is an orally multikinase
inhibitor targeting VEGFR, c-kit, RET, FGFR, PDGFR, and
serine/threonine kinases (RAF and p38MAPK). A phase II
trial (NCT00664326) on 33 patients treated with BAY 73-
4506 160mg once daily on a 3-week on/1-week off schedule
showed 27% PR and a 42% SD [34].
Brivanib and vandetanib represent two more members
of the VEGF-related antiangiogenic family. Brivanib is an
oral, dual VEGFR-2 and FGFR-1 tyrosine kinases inhibitor.
A phase II, open-label investigation conducted to assess is
activity inmRCCpatients has been opened inNovember 2010
(NCT01253668). On the other hand, vandetanib, also known
as ZD6474, is an antagonist of VEGFR and EGFR. A phase
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II trial (NCT01372813) has been terminated for insufficient
accrual.
In 2006, Jermann et al. [35] published the results of a
phase II trial of gefitinib, a low-molecular-weight epidermal
growth factor receptor (EGFR) TKI, in patients with locally
advanced, metastatic, or relapsed RCC.They did not observe
objective responses (OR), although 14 patients (53.8%) had
SD. Treatment was generally well tolerated. Furthermore,
gefitinib was also evaluated in combination with pegylated
IFN𝛼, without obtaining significant results [36].
The development of XL999 and tandutinib was stopped
due to their toxicity profiles. In 2006, a phase II trial
(NCT00277316) was opened to investigate the activity of
XL999, a multiple inhibitor of VEGFR, PDGFR, FGFR, FLT-
3, and Src.The employment of this molecule was stopped due
to the cardiac AEs revealed in the participants of this study.
In the same year, Shepard et al. [37] evaluated the efficacy and
tolerability of tandutinib, an oral inhibitor of type III tyrosine
kinase receptor kinases, observing absence of clinical activity
and excessive toxicity in these patients.
Finally, the list of novel TKI agents presently under
study also includes crizotinib, an anaplastic lymphoma kinase
(ALK), and c-Met TKI (CREATE, NCT01524926) and BIBF
120, which is under evaluation versus sunitinib in untreated
mRCC patients (NCT01024920).
3. Anti-VEGFR Dual Strategy:
mAb and Derivatives
Since the approval of bevacizumab in 2009 for the treatment
of RCC patients, several VEGF/VEGFR blocking agents
have been developed, such as VEGF-Trap and ramucirumab.
VEGF-Trap (AVE0005, ziv-aflibercept) is a VEGF-blocking
agent with both higher affinity and activity than bevacizumab
[38]. It is a derivative of VEGFR1 and VEGFR2 [38], with
minimal interactions with extracellular matrix, and this
property may be the key to its satisfying pharmacokinetic
profile. At present, a phase II trial (NCT00357760) is in
course in patients who must have received at least one prior
treatment with a TKI for metastatic ccRCC. VEGF-Trap (ziv-
aflibercept).Themain side effects revealed in the phase I trial
were proteinuria (37%), fatigue (32%), injection site reactions
(18%), nausea (17%), myalgia and anorexia (16% each),
hypertension (13%), and voice hoarseness (11%), with 7% of
grades 3-4 events [39].
Ramucirumab (IMC-112-1B) is a fully human IgG1 mAb
targeting VEGFR-2, used in a phase II trial (NCT00515697).
The results obtained, however, (49% SD lasting over 5
months, 6 months PFS) must be confirmed in randomized
trials on TKI-refractory mRCC patients.
4. Targeting mTor Pathway at Several Levels:
mTor, AKT, and PI3K Inhibitors
Recent strategies against mTor pathway include the use
of selective inhibitors of mTOR, AKT, or PI3K and dual
PI3K/mTOR inhibitors. Between the emerging mTOR
inhibitors, ridaforolimus (AP23573) [40] and AZD8055 [40]
have been demonstrated to be active in RCC patients. Rida-
forolimus is an mTOR complex 1 (MTORC1) selective
inhibitor that has been studied in phase I trial [39]
administered as a 30-minute intravenous infusion once daily
for 5 consecutive days every 2 weeks (QDx5) in a 28-day
cycle. On the basis of this study, a dose of 12.5mg/d is being
evaluated in phase II trials. Ridaforolimus is currently under
evaluation even in combination with vorinostat, an HDAC
inhibitor (NCT01169532), and with AKT inhibitor MK2206
or 𝛾-secretase inhibitor MK-0752 in patients with advanced
solid tumors (NCT01295632).
On the other hand, AZD8055, a dual mTORC1 and
mTORC2 inhibitor, has been tested in a phase I clinical
trial at different doses (NCT00731263), showing a maximum
tolerated dose (MTD) of 90mg BID [41].
Moreover, perifosine, an AKT andMAP kinase inhibitor,
has been evaluated in a phase II trial (NCT00448721) in
24 patients who had experienced disease progression after
receiving either sorafenib or sunitinib.This study revealed 8%
PR, 42% SD at 12 weeks, and amedian PFS pf at 19 weeks.The
most common grades 3 and 4 adverse events were dyspnea
(8%), hyponatremia (8%), pulmonary embolism (4%), and
arthralgia (4%) [42]. Two separate phase I trials have inves-
tigated its use in combination with sunitinib (NCT00399152)
or sorafenib (NCT00398814), observing in both cases a good
tolerability and promising results in stabilizing kidney cancer.
The efficacy of MK2206, another AKT inhibitor, is presently
under evaluation in a phase II trial (NCT01239342) versus
everolimus in refractory RCC patients.
Concerning PI3K inhibitors, BKM-120 is presently under
evaluation in several clinical trials, administered alone or in
combination with bevacizumab in patients who have failed at
last one prior anti-VEGF therapy (NCT01283048).
Finally, this family also includes dual PI3K/mTOR
inhibitors, such as NVP-BEZ235 and GDC-0980. NVP-
BEZ235, a dual PI3K/mTOR inhibitor, has been demon-
strated to reduce in vitro cell proliferation by inducing
nuclear translocation of p27 and to downregulate Akt, Mnk-
1, eIF4E, and 4EBP-1 phosphorylation and cyclin D1 and
HIF2𝛼 compared to rapamycin [43]. In July 2011, Roulin et
al. evaluated in vitro the combination between NVP-BEZ235
and sorafenib, resulting in reduced tumour cell proliferation
and increased tumour cell apoptosis in vitro [44]. Moreover,
NVP-BEZ235 is under study with everolimus in a phase I
trial (NCT01482156). With regard to GDC-0980, it is under
evaluation in comparison with everolimus in mRCC patients
progressed on VEGF-targeted therapy (NCT01442090).
5. Novel Emerging Targets and
Future Directions
The role of angiopoietin/Tie2 pathway in tumor angiogenesis
has led to the development of several inhibiting agents, such
as AMG386 and PF-4856884.Their action alone or in combi-
nation with TKIs is subject of ongoing clinical trials.The effi-
cacy and tolerability of trebananib (AMG 386) plus sorafenib
have been tested in 152 ccRCC patients receiving sorafenib
400mg orally twice daily plus intravenous AMG 386 at
10mg/kg (arm A) or 3mg/kg (arm B) or placebo (arm C)
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once weekly. PFS was not significantly different in three
groups, which all revealed high frequency of AEs, such as
diarrhea (70% in patients receiving 10mg/kg AMG 386 and
67% in those receiving 3mg/kg), hand-foot syndrome (52 and
47%), alopecia (50 and 45%), and hypertension (42 ad 49%)
[45]. In addition, AMG 386 has been evaluated in combina-
tionwith sunitinib in 85mRCCpatients näıve to angiogenesis
inhibitors, treated with sunitinib 50mg PO QD (4 weeks
on, 2 weeks off) plus AMG 386 at 10mg/kg (A) or 15mg/kg
(B). Median OR rate (ORR) was 58% in group A, including
1 CR, and 59% in group B. This combination appeared to be
tolerable, with 16% (A) and 29% (B) AMG 386 discontinua-
tions due toAEs [46]. At present, AMG-386 is under studying
also in combination with temsirolimus (NCT01548482).
Recent advances concerning the role of integrin receptors
in tumor angiogenesis have led to the development of
volociximab. It is a high-affinity anti-𝛼5𝛽1 integrin mAb, able
to avoid 𝛼5𝛽1 integrin binding to fibronectin in the ECM,
thus inducing apoptosis of ECs [47].The results coming from
a phase II study (NCT00100685) in 40 patients with clear cell
mRCC showed a stabilizing activity of volociximab, with only
one PR and 32 SD observed. Most frequent side effects were
fatigue (67.5%), nausea (35%), dyspnea (20%), and arthralgia
(17.5%), with no serious side effects observed [48].
The use of antibody-drug conjugate (ADC) has opened
novel landscapes for the treatment of RCC patients. ADC
structure is composed a mAb, able to recognize and bind
specific antigens on RCC cell surfaces, and a pro-drug acti-
vated by mAb-antigen interaction. Lymphocyte activation
antigen CD70 that is expressed on RCC cells is one of the
main targets of this new strategy. The therapeutic role of
CD70 depends on the possibility of conjugating pro-drugs
with the anti-CD70mAb.The interaction between anti-CD70
mAb and CD70 on tumor cell surfaces led to prodrug release
and activation. MDX-1203 is an mAb directed against the
human CD70 molecule conjugated with an analogue of CC-
1065 (rachelmycin) as prodrug. Its antitumor activity is due
to the alkylating action of CC-1065 on adenine, leading to
a reduced proliferation of CD70+ tumor cells [49]. MDX-
1203 is actually in course of evaluation in a phase I study
(NCT00944905) in patients with advanced/recurrent clear
cell RCC. Moreover, MDX-1411 and SGN-75, two anti-CD70
Ab-drug conjugates, are in course of evaluation in pretreated
ccRCC patients (NCT00656734 and NCT01015911, resp.).
A different approach consists in the use of radio-labeled
mAb against antigens expressed on RCC cells surface. The
G250 antigen has been identified as carbonic anhydrase
isoenzyme 9 (MN/CA IX). It is expressed in over 95% of RCC
cells and it is absent in normal kidney [50].The radio-labeled
mAb targeting G250 is currently employed in several clinical
trials. Recently, the chimeric mAb cG250 has been demon-
strated in in vitro studies to induce antibody-dependent
cellular cytotoxicity (ADCC) against G250+ RCC cells [51].
The employment of G250 in the diagnosis and treatment of
RCC is under evaluation.
Histone deacetylase (HDAC) determines the acetylation
status of histones, thus regulating gene expression. In 2004,
Shao et al. reported that aberrant HDAC activity plays a rele-
vant role in carcinogenesis [52]. HDAC catalyses the removal
of acetyl groups from N-acetyl lysine on a histone. The
effects of HDAC inhibitors include the activation of cyclin-
dependent kinase inhibitor p21WAF1/CIP1 [53] and the
p53/p21 pathway activation [54]. The mechanism underlying
HDAC-related apoptosis in tumor cells is still unclear, but it
seems to involve the recruitment of Bcl-2 family members.
LBH589 (panobinostat) is a nonselective HDAC inhibitor
interfering with the deacetylation process. Its activity has
been tested in RCC and haematologicalmalignancies. Results
from a phase II study [55] conducted in twenty patients who
had received at least one prior TKI and one mTOR inhibitor,
demonstrated no ORs, although panobinostat was well tol-
erated. Recently, a phase II trial (NCT01037257) has been
opened to investigate its activity in combination with ever-
olimus.
In the last years, the list of therapeutic targets has widely
enlarged, including at present the signal transducer and
activator of transcription 3 (STAT 3), Notch homolog 1
translocation-associated (Notch-1), dysmorphic ECs, and
nucleolin. Preliminary results from further clinical trials are
helpful to assess their role in the future RCC treatment
landscape.
STAT 3 is involved in several signaling pathways, reg-
ulating cell survival, proliferation, and angiogenesis, and it
is aberrantly activated in RCC [56]. In a recent study, the
activity of WP1066, a STAT 3 inhibitor, has been tested in
vitro in RCC lines and in vivo on murine xenografts; the
results obtained show an antiproliferative activity related to
a reduction in tubulogenesis [57].
Notch pathway is involved in cell communication and
angiogenesis representing a potential target for anticancer
therapy. The development of gamma-secretase/Notch sig-
naling pathway inhibitor RO4929097 has led to novel
perspectives, and it has been approached in a phase I
trial (NCT01141569) in mRCC patients that have failed
VEGF/VEGFR therapy.
The main objective of vascular targeting agents is to
inhibit tumor angiogenesis and to avoid the formation of
new sprouting vessels. A different approach may be realized
by the use of vascular-disrupting agents (VDAs). VDAs
recognize and disrupt the already existing tumor vessels by
targeting dysmorphic ECs. VDAs include small molecules
and ligand-directed agents. Most of the small molecules are
tubulin inhibitors, while ligand-directed agents are mainly
flavonoids.Their action results in a local production of TNF-
alpha and other cytokines.
Finally, the discovery and development of anticancer
aptamers may provide an important contribution to RCC
treatment. Aptamers are short DNA, RNA, or peptide oli-
gomers able to assume a specific and stable three-dimensional
shape in vivo [58]. The 26-mer DNA aptamer AS1411 is
currently undergoing clinical evaluation in acute myeloid
leukemia (AML), RCC (NCT00740441), and several other
solid tumors. AS1411 is internalized inside tumor cells by
specific binding to nucleolin. Nucleolin is involved in several
cellular activities, such as mRNA stabilization and ribosome
assembly [59]. AS1411 activity seems to be related to its decoy
action, which interferes with the stabilization of bcl-2 mRNA
by nucleolin, inducing cell death [60].
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Table 1: Novel targeted agents currently under evaluation for mRCC.
Agent Description Trial ID number Phase Design
Brivanib Dual VEGFR2 and FGFR-1 NCT01253668 II RCC patients after prior treatment with TKI orbevacizumab
Crizotinib Alk and c-MET TKI NCT01524926 II Patients with solid tumors
BIBF 120 VEGFR 1–3 PDGFR andFGFR TKI NCT01024920 II versus sunitinib in untreated mRCC patients
VEGF-Trap Soluble decoy receptor;derivative of VEGFR1 NCT00357760 II ccRCC patients after at least 1 prior treatment with TKI
Ridaforolimus MTORC1 selectiveinhibitor
NCT01169532 I In combination with vorinostat in patients with solidtumors
NCT01295632 I In combination with MK2206 or 𝛾-secretase inhibitorMK-0752 in patients with advanced solid tumors
MK-2206 AKT inhibitor NCT01239342 II Versus everolimus in refractory RCC patients
NVP-BEZ235 Dual PI3K/mTOR inhibitor NCT01482156 I In combination with everolimus in patients withadvanced solid tumors
GDC-0980 Dual PI3K/mTOR inhibitor NCT01442090 II In comparison with everolimus in mRCC patientsprogressed on VEGF-targeted therapy
AMG-386 Ang-1/2 inhibitor NCT01548482 II In combination with temsirolimus in patients withadvanced solid tumors
MDX-1203 Anti-CD70 Ab-drugconjugate NCT00944905 I Pretreated ccRCC or B-cell non-Hodgkin’s lymphoma
MDX-1411 Anti-CD70 Ab-drugconjugate NCT00656734 I ccRCC pts treated with up to 6 prior systemic therapies
SGN-75 Anti-CD70 Ab-drugconjugate NCT01015911 I Pretreated ccRCC or B-cell non-Hodgkin’s lymphoma
Girentuximab Chimeric mAb cG250 NCT00087022 III Adjuvant cG250 versus placebo in pts with ccRCC andhigh risk of recurrence
cG250-Lu177 Lutetium-177 labeledcG250 NCT00142415 II pts with advanced and progressive ccRCC
90Y-cG250 Yttrium-90 labeled cG250 NCT00199875 I pts with advanced and progressive ccRCC
Panitumumab Anti-EGFR mAb NCT00425035 II mRCC pts näıve or after cytokine treatment
Vorinostat HDAC inhibitor NCT00278395 II mRCC pts näıve or after cytokine treatment
RO4929097 𝛾-secretase/Notch inhibitor NCT01141569 II ccRCC pts after anti-VEGF and/or mTOR inhibitorand/or immunotherapy failure
AS1411 26-mer DNA aptamer NCT00740441 II ccRCC pts after at least 1 prior treatment with TKI
6. Discussion
The advent of targeted therapy has dramatically improved the
outcome of mRCC patients. From the approval of sorafenib
in 2005, the FDA sequentially approved sunitinib in 2006,
temsirolimus in 2007, everolimus, bevacizumab combined
with interferon alpha (IFN-𝛼), and pazopanib in 2009, and
lastly axitinib in 2012. Based on the results obtained by these
agents, a large number of drugs have been developed and are
currently under evaluation in RCC patients (Table 1). Nev-
ertheless, the efficacy of these agents seems to be influenced
by several factors. The analysis of clinical trials described in
this review reveals that toxicity and drug resistance are the
main driving forces in continuing research and development
of novel agents. The toxicity profiles of emerging molecules
result mild to moderate, showing relevant grade 3 and grade
4 adverse event rates (range 7–16.1%). Only volociximab
showed no serious adverse events. Although there were
differences between the frequencies of PR observed in these
trials, all investigated agents were characterized by the lack of
CR. These negative data should be a strong stimulus for the
creation of new therapeutic approaches.
Primary or acquired resistance to TKIs and mTOR
inhibitors has become a major focus for cancer researchers.
Primary resistance is less common and seems to be linked
to an intrinsic redundancy of tumor available angiogenic sig-
nals. On the other hand, acquired resistance is the expression
of an “angiogenic switch,” which consists in upregulation of
the existing VEGF pathway associated with the recruitment
of alternative proangiogenic factors. Current designed pre-
clinical and clinical trials include sequential and combination
regimens, aimed at providing a complete blockade of the
VEGF pathway. Observing preliminary results, in spite of a
mild improvement of patients’ outcome, combined therapies
have shown a moderate to severe increase of adverse events.
Beyond the toxicity reported, the realization of combined
regimens is also limited by their high costs that make them
feasible in experimental trials but not in clinical practice.
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Moreover, the development of novel effective agents
parallels the request of new clinical and molecular predictive
and prognostic biomarkers. Their role should be even more
relevant if associated with an improved evaluation of tumoral
response to antiangiogenic therapy. Finally, an extended
knowledge of tumor carcinogenesis process may afford novel
tools to optimize treatment regimens. Further clinical trials
are still needed to improve the outcome of mRCC patients.
7. Conclusion
Data gathered from ongoing trials will surely improve the
management of mRCC patients, even if it is difficult to define
the relevance of each one’s individual contribution. Prelim-
inary results from ongoing trials thus constitute a basis for
moderate enthusiasm, but a dramatic improvement ofmRCC
patient outcomes seems still so far.
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